News & Analysis as of

Financing Biotechnology

Dechert LLP

Overview of financing options for French biotech companies

Dechert LLP on

The trajectory of a biotech company is often full of ups and downs, influenced by unpredictable changes in market conditions. It is therefore imperative for biotech companies to be agile in finding the most appropriate...more

Fenwick & West LLP

Reflections on the J.P. Morgan Healthcare Conference: Key Themes for 2024

Fenwick & West LLP on

The Fenwick life sciences team recently returned from the 2024 JP Morgan Healthcare conference. As we reflect back on the week, there were several key themes and trends that we expect will continue to resonate and evolve over...more

Morgan Lewis - As Prescribed

Tips for Preparing Biotechnology Companies for Their First Financing Round

Welcome to day two of our Biotech Week Boston blog takeover, during which As Prescribed will shine a light on our lawyers working in the City on a Hill, who contribute their local perspectives to the counsel our global life...more

Hogan Lovells

Strategic financial options for clinical stage life sciences companies in a troubled equity market

Hogan Lovells on

Early 2023 has seen new and unprecedented financial challenges for clinical stage life sciences companies. The financing rounds of 2021 and 2022 are starting to run off, while at the same time the equity markets are either...more

Cooley LLP

Navigating the Downturn: Biotech Financing Trends

Cooley LLP on

Key takeaways - In 2022, markets have exhibited volatility and general weakness across the board, in part due to inflation and corresponding interest rate hikes. As a result, equity capital markets have had their slowest...more

Manatt, Phelps & Phillips, LLP

Delivering Breakthrough Treatments Affordably

Editor’s Note: In a recent webinar, Manatt Health’s Anthony Fiori, Senior Managing Director, and Alex Dworkowitz, Partner, hosted a panel of innovative thought leaders—including Dr. Sanjiv Shah, Chief Medical Officer of...more

Rothwell, Figg, Ernst & Manbeck, P.C.

Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO

Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the most lucrative IPOs in gene-editing. In June 2021, Gene editing...more

Carlton Fields

Court Remands Arbitration Award to Arbitrator for Clarification

Carlton Fields on

Three Brothers Trading LLC d/b/a Alternative Execution Group (AEXG) and Generex Biotechnology Corp. entered into a contract whereby AEXG would secure investors for Generex’s business and, in exchange, Generex would pay AEXG a...more

McGuireWoods LLP

Healthcare & Life Sciences Private Equity Deal Tracker: Atreca Secures $56 Million in Funding

McGuireWoods LLP on

Atreca has announced it has secured $56 million in series A funding. Atreca, based in Redwood City, California, is a privately held biotechnology company developing therapeutics drawn from human immune responses,...more

McGuireWoods LLP

Healthcare & Life Sciences Private Equity Deal Tracker: Metacrine Secures $36 Million in Financing

McGuireWoods LLP on

Metacrine, based in San Diego, Calif., is a biotechnology company focused on advancing research in nuclear hormone receptors for treatment of metabolic diseases originated at the Salk Institute for Biological Studies....more

Fenwick & West LLP

Life Sciences Financing Survey - First Half, 2013

Fenwick & West LLP on

In This Issue: - Summary - Analysis of Industry Data - Detailed Fenwick & West Results: Valuation - Detailed Fenwick & West Results: Financing Terms ...more

Mintz - Energy & Sustainability Viewpoints

Funding for New Biobased Chemical Plants May Be Found Overseas, ACORE Official Says

Originally published in the Daily Environment Report on November 15, 2013. PHILADELPHIA–Finding funding to build new facilities to produce biobased chemicals and biofuels is challenging in the current economic...more

12 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide